345 Another triple agonist for these receptors, LY3437943, was found to induce robust reductions in plasma glucose and bodyweight in overweight individuals with T2D, demonstrating that this triple agonist could be a future therapeutic option for T2D treatment
She considers the recent IMCIVREE Phase 2 results in HO incredibly impressive. She was particularly impressed with the magnitude of the weight loss in a relatively short 16-week treatment period
Ingredients: L-carnitine-L-tartrate, capsule (hydroxypropylmethylcellulose), gelling agent (magnesium salts of fatty acids), bulking agent (microcrystalline cellulose), anti-caking agent (silicon dioxide)
Conversely, broader access may increase total utilization while lowering net cost per unit
Currently, 10 GLP - 1 drugs have been approved in China, and there are more domestic varieties queuing up for market launch